Numerous vaccine technology platforms evolved over the past few decades. Today, addressing disease outbreaks and protecting the immuno-compromized provides population severe challenges and at the same time harbors significant growth potential.
Traditional whole-pathogen vaccine platforms, which require the cultivation of the pathogen, have a proven track record for many diseases. The newer generation of vaccine platforms like recombinant protein and the new era of nucleic acid-based vaccines solely need the pathogen’s genetic sequence. By significantly increasing the speed of development and manufacturing processes they open up new potential for a plethora of indications and a vaccine development process in a speed that has never been achieved before.